104 related articles for article (PubMed ID: 20015559)
1. Monopoly pricing of an antibiotic subject to bacterial resistance.
Herrmann M
J Health Econ; 2010 Jan; 29(1):137-50. PubMed ID: 20015559
[TBL] [Abstract][Full Text] [Related]
2. Reference pricing of pharmaceuticals.
Brekke KR; Königbauer I; Straume OR
J Health Econ; 2007 May; 26(3):613-42. PubMed ID: 17188769
[TBL] [Abstract][Full Text] [Related]
3. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry.
Suh DC; Manning WG; Schondelmeyer S; Hadsall RS
Health Serv Res; 2000 Jun; 35(2):529-47. PubMed ID: 10857475
[TBL] [Abstract][Full Text] [Related]
4. The effect of generic competition on the price of brand-name drugs.
Lexchin J
Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
[TBL] [Abstract][Full Text] [Related]
5. Antibiotic development: a victim of market forces?
Tillotson GS
IDrugs; 2008 May; 11(5):340-6. PubMed ID: 18465675
[TBL] [Abstract][Full Text] [Related]
6. Societal costs versus savings from wild-card patent extension legislation to spur critically needed antibiotic development.
Spellberg B; Miller LG; Kuo MN; Bradley J; Scheld WM; Edwards JE
Infection; 2007 Jun; 35(3):167-74. PubMed ID: 17565458
[TBL] [Abstract][Full Text] [Related]
7. The antibacterial drugs market.
Kresse H; Belsey MJ; Rovini H
Nat Rev Drug Discov; 2007 Jan; 6(1):19-20. PubMed ID: 17269159
[No Abstract] [Full Text] [Related]
8. Generic medicine pricing in Europe: current issues and future perspective.
Simoens S
J Med Econ; 2008; 11(1):171-5. PubMed ID: 19450118
[TBL] [Abstract][Full Text] [Related]
9. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
[TBL] [Abstract][Full Text] [Related]
10. Competition between brand-name and generics--analysis on pricing of brand-name pharmaceutical.
Kong Y
Health Econ; 2009 May; 18(5):591-606. PubMed ID: 18816580
[TBL] [Abstract][Full Text] [Related]
11. The impact of pricing and patent expiration on demand for pharmaceuticals: an examination of the use of broad-spectrum antimicrobials.
Kaier K
Health Econ Policy Law; 2013 Jan; 8(1):7-20. PubMed ID: 22947241
[TBL] [Abstract][Full Text] [Related]
12. Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals.
Kesselheim AS; Outterson K
Health Aff (Millwood); 2010 Sep; 29(9):1689-96. PubMed ID: 20820028
[TBL] [Abstract][Full Text] [Related]
13. Antibiotics: a shot in the arm.
Leeb M
Nature; 2004 Oct; 431(7011):892-3. PubMed ID: 15496888
[No Abstract] [Full Text] [Related]
14. Antibacterial drug discovery: is it all downhill from here?
Projan SJ; Shlaes DM
Clin Microbiol Infect; 2004 Nov; 10 Suppl 4():18-22. PubMed ID: 15522036
[TBL] [Abstract][Full Text] [Related]
15. Antibiotics at the crossroads.
Nathan C
Nature; 2004 Oct; 431(7011):899-902. PubMed ID: 15496893
[No Abstract] [Full Text] [Related]
16. The impact of generic substitution on price competition in Finland.
Aalto-Setälä V
Eur J Health Econ; 2008 May; 9(2):185-91. PubMed ID: 17508226
[TBL] [Abstract][Full Text] [Related]
17. Price regulation and generic competition in the pharmaceutical market.
Dalen DM; Strøm S; Haabeth T
Eur J Health Econ; 2006 Sep; 7(3):208-14. PubMed ID: 16841230
[TBL] [Abstract][Full Text] [Related]
18. How property rights and patents affect antibiotic resistance.
Horowitz JB; Moehring HB
Health Econ; 2004 Jun; 13(6):575-83. PubMed ID: 15185387
[TBL] [Abstract][Full Text] [Related]
19. Effect of generic drug competition on the price of prescription drugs in Ontario.
Lexchin J
CMAJ; 1993 Jan; 148(1):35-8. PubMed ID: 8439888
[TBL] [Abstract][Full Text] [Related]
20. Ownership of knowledge--the role of patents in pharmaceutical R&D.
Correa CM
Bull World Health Organ; 2004 Oct; 82(10):784-7; discussion 787-90. PubMed ID: 15643801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
